Typhoid Fever: all 76 studies
Page 1 of 1. Open to participants first (11), then studies with results posted, then the rest; newest registration first within each.
- Curcumin Extract Added to Ciprofloxacin for Typhoid Carriers Among Food Handlers of the Free Nutritious Meal ProgramNot yet recruitingNCT07908030Phase 2
- COMPARISON OF SINGLE VERSUS COMBINATION DRUG THERAPY IN EXTENSIVELY DRUG RESISTANT SALMONELLA TYPHI IN TERMS OF TIME TO DEFERVESCENCENot yet recruitingNCT07641348Not applicable
- Meropenem vs Azithromycin Efficacy in Case XDR Enteric FeverRecruitingNCT07314281Phase 4
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in InfantsRecruitingNCT07286370Phase 2
- Long-Term Protection of Vi Antibodies Induced by Bio TCV in Indonesian Population Compared to PQed TCVNot yet recruitingNCT06921460
- ZyVac-TCV Bangladesh StudyNot yet recruitingNCT06757283Phase 3
- Co-administration Study of OCV, TCV and MRNot yet recruitingNCT05771779Phase 3
- Transcriptomic Responses for the Identification of PathogensRecruitingNCT04878549
- Evaluation of Typhoid Conjugate Vaccine Effectiveness in GhanaRecruitingNCT04852185Phase 4
- Blood Donor CVD 5000RecruitingNCT03971669Phase 4
- CVD 38000: Study of Responses to Vaccination With Typhoid and/or CholeraRecruitingNCT03705585Phase 4
- Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy AdultsCompletedNCT05613205Phase 1Results posted
- Study to Evaluate the Safety, Tolerability and Immunogenicity of a Potential Enteric Fever VaccineCompletedNCT04349553Phase 1Results posted
- Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese SubjectsCompletedNCT01608815Phase 3Results posted
- A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in AdultsCompletedNCT01466387Phase 3Results posted
- Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in AdultsCompletedNCT01438996Phase 2Results posted
- Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and InfantsCompletedNCT01437267Phase 2Results posted
- Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and InfantsCompletedNCT01229176Phase 2Results posted
- Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old)CompletedNCT01193907Phase 2Results posted
- Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)CompletedNCT01123941Phase 1Results posted
- Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy AdultsCompletedNCT00679172Phase 2Results posted
- Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in InfantsCompletedNCT00342628Phase 2Results posted
- Immunogenicity and Tolerability of Booster Typhoid Conjugate Vaccine (TCV) 5-6 Years After Initial Dose in Children in Burkina FasoCompletedNCT07624175Phase 2
- This Randomized Controlled Trial Evaluates the Comparative Efficacy of Intravenous Meropenem Alone Versus Intravenous Meropenem Combined With Oral Azithromycin in Children Aged 6 Months to Under 5 Years Diagnosed With Blood Culture-confirmed Extensively Drug-resistant Uncomplicated Typhoid FeverCompletedNCT07445282Phase 4
- Efficacy of Levofloxacin Versus Ciprofloxacin in the Treatment of Childhood Typhoid FeverCompletedNCT07150065Phase 2
- Diagnosis and Staging of Typhoid Fever Using Surface-enhanced Raman Spectroscopy Liquid BiopsyCompletedNCT06546982Not applicable
- Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) VaccinesCompletedNCT06104345Phase 4
- Challenge Non-Typhoidal Salmonella (CHANTS) StudyActive, not recruitingNCT05870150Not applicable
- Evaluation Study of DPP® Typhoid AssayCompletedNCT05579821
- TyVECO: Surveillance ProtocolStatus unknownNCT05562102
- Vellore Typhoid Vaccine Impact TrialCompletedNCT05500482Phase 4
- Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine 'Typhocon' in BangladeshCompletedNCT05475379Phase 1/2
- Effectiveness of a Typhoid Conjugate Vaccine in DRCStatus unknownNCT05119426Phase 4
- Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged ParticipantsCompletedNCT04830371Phase 2/3
- Commercial Typhoid Tests Validation TrialCompletedNCT04801602
- Commercial Typhoid Tests ValidationStatus unknownNCT04673487
- WHNRC (Western Human Nutrition Research Center) Fiber Intervention StudyCompletedNCT04543877Early Phase 1
- The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial)CompletedNCT04349826Phase 4
- Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRCStatus unknownNCT04235361
- Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)CompletedNCT04204096Phase 3
- Comparison of Two Drugs Regimen in Treatment of Complicated Typhoid Fever in ChildrenCompletedNCT04154722Phase 4
- Induction of Gut Permeability by an Oral VaccineActive, not recruitingNCT04083950Early Phase 1
- CVD 37000: Immunity and Microbiome Studies at Intestinal and Systemic Sites in Ty21a Vaccinated AdultsActive, not recruitingNCT03970304Phase 4
- Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy AdultsCompletedNCT03956524Phase 1
- Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate VaccineStatus unknownNCT03933098Phase 3
- Safety and Immunogenicity of Typhax, a Typhoid VaccineCompletedNCT03926455Phase 1
- Understanding How Salmonella Typhi Infects Humans (Bottlenecks)CompletedNCT03889067Not applicable
- Typhoid Conjugate Vaccine Trial Among Children Younger Than 2 Years in Ouagadougou, Burkina FasoCompletedNCT03614533Phase 2
- Cellular Immune Responses in Typhoid Fever Patients and VaccineesStatus unknownNCT03600025Phase 1
- Typhoid Conjugate Vaccine Introduction in Navi Mumbai, IndiaCompletedNCT03554213
- Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate VaccineCompletedNCT03527355Phase 2
- Effects of Aging on Primary and Secondary Vaccine ResponsesCompletedNCT03312699Phase 1
- Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, MalawiActive, not recruitingNCT03299426Phase 3
- Investigating Typhoid Fever PathogenesisStatus unknownNCT03067961Not applicable
- Global Genomic and Proteomic Profiling of African Children With Typhoid FeverCompletedNCT02947295
- Nepal Undifferentiated Febrile Illness TrialCompletedNCT02773407Phase 3
- Safety and Immunogenicity of a Vi-DT Typhoid Conjugate VaccineCompletedNCT02645032Phase 1
- Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among TravelersCompletedNCT02391909
- Vaccines Against Salmonella TyphiCompletedNCT02324751Phase 2
- Typhoid Fever: Combined vs. Single Antibiotic TherapyStatus unknownNCT02224040Phase 4
- Investigating Enteric Fever - Salmonella Typhi and Paratyphi Challenge StudyCompletedNCT02192008Not applicable
- Understanding Paratyphoid InfectionCompletedNCT02100397Not applicable
- Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever)CompletedNCT01766830Not applicable
- Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric FeverCompletedNCT01421693Phase 4
- Understanding Typhoid Disease After VaccinationCompletedNCT01405521Phase 2
- Studies of Immune Responses to Orally Administered Vaccines in Developing CountryCompletedNCT01019083Phase 1/2
- Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult SubjectsCompletedNCT00498654Phase 2
- Long Term Protection by and Persistence of Vi Antibodies Induced by Vi-rEPA Conjugate Vaccines in Vietnamese Children Injected at 2-5 Years or at 5-8 Years of AgeCompletedNCT00386789
- CVD 909 Vi Prime Boost StudyCompletedNCT00326443Phase 1
- Salmonella Typhi Vi O-Acetyl Pectin-rEPA Conjugate VaccineCompletedNCT00277147Phase 1
- TY800 Dose Escalation (Typhoid)CompletedNCT00269295Phase 1/2
- Comparative Study in Healthy Adults Aged 18-50 Yrs Administered With Hepatyrix or Havrix+Typherix or Tiphim Vi, to Compare Reactogenicity & ImmunogenicityCompletedNCT00197249Phase 3
- Typhoid Vi Vaccine Effectiveness in Hechi, Guangxi, ChinaCompletedNCT00131833Phase 4
- Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central VietnamCompletedNCT00131820Phase 4
- Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in ChildhoodCompletedNCT00125047Phase 4
- Evaluation of the Vi Polysaccharide Vaccine Against Typhoid FeverCompletedNCT00125008Phase 4